After nearly 4 years of what some researchers saw as foot dragging, the Drug Enforcement Administration (DEA) has announced it will evaluate 37 applications to grow marijuana for medical research and proposed new rules for the prospective growers that outline how the cannabis-growing program would work.

George Hodgin, CEO of the Biopharmaceutical Research Company, one of the applicants, says “It opens up a path for traditional drug development in the United States,” whereby researchers can conduct clinical trials and seek approval from the Food and Drug Administration (FDA) for marijuana-based therapies.

See the original article at Science